Modality
ASO
MOA
CDK2i
Target
CD20
Pathway
mTOR
MM
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Mar 2031
Phase 1Current
NCT04820806
2,586 pts·MM
2023-12→2031-03·Not yet recruiting
NCT08608017
2,495 pts·MM
2021-12→2028-09·Not yet recruiting
5,081 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-09-162.5y awayPh2 Data· MM
2031-03-014.9y awayPh2 Data· MM
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2028-09-16 · 2.5y away
MM
Ph2 Data
2031-03-01 · 4.9y away
MM
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04820806 | Phase 1/2 | MM | Not yet recr... | 2586 | CR |
| NCT08608017 | Phase 1/2 | MM | Not yet recr... | 2495 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |